Kisspeptin-10 | BioAvailable

The verdict

Our read at a glance.

Whether exact Kisspeptin-10 / KP-10 / metastin 45-54 evidence supports any claim beyond human endocrine physiology, biomarker response, registry-status context, and product-identity or safety watch.

The signal: This memo draws on 78 vetted references. Exact human KP-10/metastin 45-54 studies show endocrine and metabolic biomarker movement, including reproductive-axis hormone responses, but these are physiology signals rather than proof of clinical benefit. ClinicalTrials.gov records add status context only, including completed, withdrawn, recruiting, and terminated records. Human tissue, analytical, discovery, receptor, and animal or cell sources explain plausibility and identity boundaries without establishing routine clinical utility.
The unknown: Whether any exact KP-10 product can show reproducible clinical outcomes and acceptable safety in a defined population under modern evidence standards, and whether future records can keep KP-10 separate from KP-54, GnRH analogs, hCG, oxytocin, PT-141, KISS1R agonist analogs, broad fertility literature, and identity-uncertain market products.
Our read: Early human signal, low certainty. There is real human physiology evidence for exact kisspeptin-10, but it stops at measured physiology rather than proven clinical outcomes. The practical risk is overextension into fertility, performance, wellness, access, or use claims.

The mechanism

How it works.

Kisspeptin-10 is a ten-amino-acid fragment cut from the natural KISS1 protein and is the shortest piece that still works. It binds KISS1R on the hypothalamic neurons that release GnRH, the master trigger of reproduction, so giving it pushes those neurons to fire and the pituitary to release the hormones LH and FSH, which in turn raise sex-hormone output. Human studies confirm this hormone response, but they measure short-term blood markers, not fertility or any clinical outcome.

Safety & regulatory boundary

The consequential part.

FDA materials support a compounded-substance safety and product-identity boundary for Kisspeptin-10. No exact FDA-approved finished-drug record was identified in DailyMed/openFDA checks on 2026-05-17, which is a date-limited status note rather than a ban or approval claim. Studied KP-10/metastin 45-54 records do not validate compounded, research-use, internet-market, identity-uncertain market, or adjacent-peptide products.

What's next

What we're watching.

Watch FDA compounding and PCAC follow-up, exact ClinicalTrials.gov status changes or posted results, peer-reviewed human studies with clinical endpoints, product-identity documentation, adverse-event reporting, and source maps that keep KP-10 separate from KP-54, GnRH analogs, hCG, PT-141, KISS1R analogs, and fertility-treatment literature.

Context

Why this is discussed.

Kisspeptin-10 is discussed because it sits upstream of GnRH and reproductive-axis hormone signaling. That attention often blurs exact KP-10 physiology with Kisspeptin-54, GnRH or gonadorelin analogs, hCG, oxytocin, PT-141, fertility-treatment narratives, KISS1R agonist analogs, compounded products, research-use products, and internet-market products.

The evidence base

56 cited references.

Regulatory & labels4

FDA compounding safety-risk table entry for Kisspeptin-10

Food and Drug Administration · Current page checked 2026-05-17

FDA UNII substance record: KISSPEPTIN-10

Food and Drug Administration / GSRS · Checked 2026-05-17

FDA PCAC briefing document on Kisspeptin-10

Food and Drug Administration · 2024

FDA PCAC presentation materials on Kisspeptin-10

Food and Drug Administration · 2024